Altimmune (ALT) Gains from Investment Securities (2018 - 2022)

Altimmune (ALT) has 5 years of Gains from Investment Securities data on file, last reported at -$1.8 million in Q1 2022.

• On a quarterly basis, Gains from Investment Securities fell 302.27% year-over-year to -$1.8 million in Q1 2022; TTM through Dec 2022 was -$2.6 million, a 477.14% decrease from a year earlier, with the FY2022 full-year figure at $86000.0, down 87.71% from the prior year.
• Gains from Investment Securities for Q1 2022 stood at -$1.8 million, down from -$860000.0 in the prior quarter.
• Over the last five years, Gains from Investment Securities for ALT reached as high as $11.9 million in Q2 2020 and fell as low as -$1.8 million in Q1 2022.
• Historically, Gains from Investment Securities has averaged $2.1 million across 5 years, with a median of $442000.0 in 2018.
• Across the five-year window, Gains from Investment Securities jumped 11547.37% in 2020 and sank 302.27% in 2022, its largest moves.
• Year by year, Gains from Investment Securities stood at $4000.0 in 2018, then sank by 2000.0% to -$76000.0 in 2019, then surged by 7205.26% to $5.4 million in 2020, then plunged by 115.93% to -$860000.0 in 2021, then tumbled by 106.98% to -$1.8 million in 2022.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were -$1.8 million in Q1 2022, -$860000.0 in Q4 2021, and $1.7 million in Q3 2021.